Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8mg in Proliferative Diabetic Retinopathy (HERO)
NCT07118670Phase 4Active, not recruiting
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in proliferative diabetic retinopathy (PDR). Started Dec 2025; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT07118670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118670.